The clinical trial to examine the efficacy of the intravitreal injection of anti-VEGF antibody Bevacizumab(Avastin) for severe retinopathy of prematurity.

The clinical trial to examine the efficacy of the intravitreal injection of anti-VEGF antibody Bevacizumab(Avastin) for severe retinopathy of prematurity. - The clinical trial to examine the efficacy of the intravitreal injection of Bevacizumab for severe ROP.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018069

Enrollment

Registered

2017-06-24

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of prematurity

Interventions

Intravitreal Bevacizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)a premature baby 2)diagnosed as severe ROP 3)The patient in our hospital 4) The patient whose parents understand this study and the agreement in the document was provided.

Exclusion criteria

Exclusion criteria: 1)The patient who judged inappropriate as a subject by pediatrician. 2)In addition, the patient who judged an examination responsibility (allotment) doctor to be inappropriate as a subject

Design outcomes

Primary

Measure	Time frame
Fundus examination	—

Countries

Japan

Contacts

Public ContactSatomi Noda

Gunma University Hospital Department of Ophthalmology

s-noda@gunma-u.ac.jp027-220-8338

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026